Inhibikase Therapeutics (IKT) Income Statement (2020 - 2026)
Income Statement report data from Mar 31, 2020 to Mar 31, 2026 for Inhibikase Therapeutics (IKT).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | |||||||||||||||||||||||||
Total Revenue | - | - | - | - | - | - | - | - | - | - | 80K (-33.33%) | 120K (+100.00%) | 60K (0.00%) | 60K (+500.00%) | 10K (0.00%) | 10K (-80.00%) | 50K | - | 330K (-75.74%) | 1.36M (-3.55%) | 1.41M (+729.41%) | 170K (+325.00%) | 40K (-81.82%) | 220K (-18.52%) | 270K |
Operating Expenses | |||||||||||||||||||||||||
Research And Development | 11M (+70.44%) | 6.36M (-16.86%) | 7.65M (+45.16%) | 5.27M (-49.86%) | 11M (+46.18%) | 7.19M (+71.60%) | 4.19M (+36.04%) | 3.08M (+12.00%) | 2.75M (-8.33%) | 3.00M (-7.12%) | 3.23M (-28.85%) | 4.54M (+59.30%) | 2.85M (-6.56%) | 3.05M (+2.35%) | 2.98M (0.00%) | 2.98M (-1.32%) | 3.02M (-10.91%) | 3.39M (+7.62%) | 3.15M (+32.35%) | 2.38M (-2.06%) | 2.43M (+956.52%) | 230K (+91.67%) | 120K (-53.85%) | 260K (-7.14%) | 280K |
Selling General And Administrative | 7.38M (+9.01%) | 6.77M (+20.68%) | 5.61M (-5.24%) | 5.92M (+12.76%) | 5.25M (-8.54%) | 5.74M (+250.00%) | 1.64M (-16.75%) | 1.97M (-2.96%) | 2.03M (+45.00%) | 1.40M (-13.58%) | 1.62M (-8.99%) | 1.78M (-7.77%) | 1.93M (+44.03%) | 1.34M (-12.99%) | 1.54M (-7.23%) | 1.66M (-0.60%) | 1.67M (+1.21%) | 1.65M (+0.61%) | 1.64M (+1.86%) | 1.61M (+0.63%) | 1.60M (+40.35%) | 1.14M (+96.55%) | 580K (+56.76%) | 370K (-30.19%) | 530K |
Operating Expenses | 18M (+29.46%) | 14M (+7.91%) | 13M (+17.91%) | 11M (-25.82%) | 15M (+12.92%) | 13M (+121.78%) | 5.83M (+15.45%) | 5.05M (+5.65%) | 4.78M (+8.64%) | 4.40M (-9.28%) | 4.85M (-23.26%) | 6.32M (+32.22%) | 4.78M (+8.64%) | 4.40M (-2.65%) | 4.52M (-2.80%) | 4.65M (-0.85%) | 4.69M (-6.94%) | 5.04M (+5.00%) | 4.80M (+20.30%) | 3.99M (-0.99%) | 4.03M (+194.16%) | 1.37M (+95.71%) | 700K (+11.11%) | 630K (-22.22%) | 810K |
Depreciation And Amortization | - | - | 20K (0.00%) | 20K (+100.00%) | 10K (0.00%) | 10K (0.00%) | 10K (0.00%) | 10K (0.00%) | 10K (0.00%) | 10K (0.00%) | 10K (-93.75%) | 160K (+1500.00%) | 10K (0.00%) | 10K | - | - | - | - | - | - | - | - | - | - | - |
Operating Income | |||||||||||||||||||||||||
Operating Income | -17.84M (+29.46%) | -13.78M (+7.91%) | -12.77M (+17.91%) | -10.83M (-25.82%) | -14.60M (+12.92%) | -12.93M (+121.78%) | -5.83M (+15.45%) | -5.05M (+5.65%) | -4.78M (+8.64%) | -4.40M (-7.76%) | -4.77M (-23.06%) | -6.20M (+31.63%) | -4.71M (+8.78%) | -4.33M (-3.99%) | -4.51M (-2.80%) | -4.64M (0.00%) | -4.64M (-7.94%) | -5.04M (+12.75%) | -4.47M (+69.96%) | -2.63M (0.00%) | -2.63M (+119.17%) | -1.20M (+81.82%) | -660.00K (+60.98%) | -410.00K (-24.07%) | -540.00K |
Ebit | -17.84M (+29.46%) | -13.78M (+7.91%) | -12.77M (+17.91%) | -10.83M (-25.82%) | -14.60M (+12.92%) | -12.93M (+121.78%) | -5.83M (+15.45%) | -5.05M (+5.65%) | -4.78M (+8.64%) | -4.40M (-7.76%) | -4.77M (-23.06%) | -6.20M (+31.63%) | -4.71M (+8.78%) | -4.33M (-3.99%) | -4.51M (-2.80%) | -4.64M (0.00%) | -4.64M (-7.94%) | -5.04M (+12.75%) | -4.47M (+69.96%) | -2.63M (0.00%) | -2.63M (+119.17%) | -1.20M (+81.82%) | -660.00K (+60.98%) | -410.00K (-24.07%) | -540.00K |
EBITDA | -17.84M (+29.46%) | -13.78M (+8.16%) | -12.74M (+17.85%) | -10.81M (-25.91%) | -14.59M (+12.93%) | -12.92M (+121.99%) | -5.82M (+15.48%) | -5.04M (+5.44%) | -4.78M (+8.64%) | -4.40M (-7.56%) | -4.76M (-21.19%) | -6.04M (+28.24%) | -4.71M (+8.78%) | -4.33M (-3.99%) | -4.51M (-2.80%) | -4.64M (0.00%) | -4.64M (-7.94%) | -5.04M (+12.75%) | -4.47M (+69.96%) | -2.63M (0.00%) | -2.63M (+119.17%) | -1.20M (+81.82%) | -660.00K (+60.98%) | -410.00K (-24.07%) | -540.00K |
Other Income / Expenses | |||||||||||||||||||||||||
Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10K (0.00%) | 10K (0.00%) | 10K (0.00%) | 10K (0.00%) | 10K (0.00%) | 10K |
Net Interest Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -10.00K (0.00%) | -10.00K (0.00%) | -10.00K (0.00%) | -10.00K (0.00%) | -10.00K (0.00%) | -10.00K |
Net Income | |||||||||||||||||||||||||
Income Before Tax | - | -50.00K | - | - | - | -30.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income From Continuing Operations | -16.38M (+28.67%) | -12.73M (+6.71%) | -11.93M (+20.26%) | -9.92M (-27.49%) | -13.68M (+12.78%) | -12.13M (+109.86%) | -5.78M (+16.53%) | -4.96M (+6.67%) | -4.65M (+11.24%) | -4.18M (-9.13%) | -4.60M (-20.42%) | -5.78M (+29.02%) | -4.48M (+4.67%) | -4.28M (-4.68%) | -4.49M (-3.23%) | -4.64M (0.00%) | -4.64M (-7.94%) | -5.04M (+12.75%) | -4.47M (+69.32%) | -2.64M (0.00%) | -2.64M (+118.18%) | -1.21M (+80.60%) | -670.00K (+59.52%) | -420.00K (-23.64%) | -550.00K |
Net Income | -16.38M (+28.67%) | -12.73M (+6.71%) | -11.93M (+20.26%) | -9.92M (-27.49%) | -13.68M (+12.78%) | -12.13M (+109.86%) | -5.78M (+16.53%) | -4.96M (+6.67%) | -4.65M (+11.24%) | -4.18M (-9.13%) | -4.60M (-20.42%) | -5.78M (+29.02%) | -4.48M (+4.67%) | -4.28M (-4.68%) | -4.49M (-3.23%) | -4.64M (0.00%) | -4.64M (-7.94%) | -5.04M (+12.75%) | -4.47M (+69.32%) | -2.64M (0.00%) | -2.64M (+118.18%) | -1.21M (+80.60%) | -670.00K (+59.52%) | -420.00K (-23.64%) | -550.00K |
Comprehensive Income Net Of Tax | - | - | - | - | - | - | -5.78M (+16.53%) | -4.96M | - | - | -4.59M (-22.86%) | -5.95M | - | - | -4.47M (-3.66%) | -4.64M | - | - | - | - | - | - | - | - | - |